-
Biodegradable Capsule Designed for Hemophilia Drug
A chemical engineering group designed a capsule to deliver blood coagulating proteins for people with hemophilia B who now require injections or infusions.
-
Liquid Biopsy Better Detects Lung Cancer Mutations
Tests of blood and urine from patients with a common form of lung cancer show these liquid biopsies more accurately identified cancer-causing mutations than traditional tissue sample biopsies.
-
Another Thanksgiving Tradition
24 November 2015. Today begins Thanksgiving weekend in the United States, a day of family gatherings, feasting, football, and (for some) shopping. Last year was also the 50th anniversary of the counterculture anthem for Thanksgiving, Arlo Guthrie’s Alice’s Restaurant, a song about Thanksgiving and a lot more. And as we did last year, here’s Arlo…
-
Nylon Fibers Given Muscle-Like Bending Properties
Research engineers at MIT designed a process that gives ordinary nylon fibers the ability to bend and flex like artificial muscles.
-
Engineered T-Cell Trial Halted After Participant Dies
A clinical trial testing treatments that modify immune system cells to fight leukemia in adults was stopped after one of the patients died from inflammation in the brain.
-
Partnership Assessing Nerve Stimulation Bleeding Device
The Feinstein Institute for Medical Research and Global Good Fund are evaluating an electronic device that stimulates nerves to stop bleeding, as a way to control postpartum hemorrhage
-
Targeted Leukemia Drugs Sharply Raising Costs of Care
Drugs directly attacking cancer cell growth show high remission rates with a common form of leukemia, but a new study suggests the high costs of these drugs could impose difficult economic burdens on patients and the health care system.
-
Algae Feed Proposed to Enrich Farm Salmon Fatty Acids
A developer of feeds for farmed salmon says its algae-based feed supplements could arrest the sharp decline in omega-3 fatty acids discovered in a recent study.
-
Novartis Acquires Sickle-Cell Drug Developer
Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million.
-
Nanotech Material Found Having Anti-Bacterial Properties
A synthetic porous material developed to deliver drugs to the skin was shown in lab tests to prevent the growth of bacteria on its surfaces.